FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound of formula (IA) or (IB), or a pharmacologically acceptable salts thereof, wherein R2a, R2b, R2c are independently specified in H, halogen and C1-C6alkyl; Y represents -O- or -S(O)p-, wherein p is equal to 0, 1 or 2; and R1 represents a radical of formula (IIC), wherein T represents -N or -CH; R3 represents H or F.
EFFECT: invention refers to a pharmaceutical composition possessing activity inhibiting p38 MAP kinase, and using them for treating bronchopulmonary diseases.
15 cl, 4 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
UREA DERIVATIVES AND THERAPEUTIC USE THEREOF IN TREATING, AMONG OTHER THINGS, RESPIRATORY TRACT DISEASES | 2011 |
|
RU2586223C2 |
NEW COMPOUNDS | 2016 |
|
RU2747645C2 |
DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE-1-YL-UREA AND THEIR USE IN TREATMENT, INTER ALIA, DISEASES OF RESPIRATORY TRACT | 2011 |
|
RU2586333C1 |
KINASE INHIBITORS | 2012 |
|
RU2623734C9 |
P38 KINASE-INHIBITING AGENTS | 2010 |
|
RU2532376C2 |
COMPOSITIONS AND METHODS FOR JAK PATH INHIBITION | 2011 |
|
RU2672100C2 |
2-OXINDOLE COMPOUNDS | 2017 |
|
RU2743747C2 |
DIARYL-SUBSTITUTED 6,5-CONJUGED CYCLIC COMPOUNDS AS C5aR INHIBITORS | 2018 |
|
RU2796983C2 |
KINASE INHIBITORS | 2013 |
|
RU2637944C2 |
NOVEL COMPOUNDS | 2012 |
|
RU2598840C2 |
Authors
Dates
2014-05-20—Published
2010-02-16—Filed